Skip to main content

Table 3 Matters relating to conservative treatment

From: Factors affecting pregnancy outcomes in young women treated with fertility-preserving therapy for well-differentiated endometrial cancer or atypical endometrial hyperplasia

  Total Pregnancy Non-pregnancy P*
Age of pregnancy permission 35.0 ± 4.7 33.9 ± 4.4 36.0 ± 4.8 0.023
Number of D&C (times) 4.98 ± 3.27 4.18 ± 2.34 5.66 ± 3.77 0.049
Endometrial thickness during ovulation (mm) 7.50 ± 2.08 8.56 ± 1.87 6.70 ± 1.87 <0.001
Duration of MPA administration (days) 357.7 ± 285.4 277.5 ± 167.0 431.5 ± 342.5 0.010
Periods of disappearance of lesions (days) 164.0 ± 143.1 136.2 ± 133.8 187.0 ± 147.7 0.042
Periods from the last MPA administration to menstruation or starting date of the pregnancy (days)   314.0 ± 392.8
Infertile period after conservative treatment (days) 1146 ± 1024 1206 ± 887 1096 ± 1131 0.116
Follow up (days) 2032 ± 1266 2027 ± 1115 2037 ± 1389 0.592
Recurrence (%) 61 (62.2) 23 (51.1) 38 (71.7) 0.036
Intrauterine adhesion (%) 20/81 (24.7) 5/29 (17.2) 15/52 (28.8) 0.191
  1. Note : Values listed as mean ± standard deviation
  2. *Pregnancy versus Non-pregnancy (Mann–Whitney U test)